Cytogen, Inc. (KOSDAQ:217330)
South Korea
· Delayed Price · Currency is KRW 3,980.00
+320.00 (8.74%)
Last updated: Jun 10, 2025
Cytogen Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | 15,712 | 10,911 | 3,184 | 760.78 | 347.85 |
| Other Revenue | - | - | -0 | - | - |
| Revenue | 15,712 | 10,911 | 3,184 | 760.78 | 347.85 |
| Revenue Growth (YoY) | 380.67% | 242.63% | 318.57% | 118.71% | - |
| Cost of Revenue | 11,628 | 8,081 | 2,338 | 565.59 | 290.57 |
| Gross Profit | 4,084 | 2,829 | 846.22 | 195.19 | 57.28 |
| Selling, General & Admin | 9,449 | 9,076 | 8,171 | 7,595 | 8,519 |
| Research & Development | 2,512 | 2,840 | 3,117 | 3,198 | 3,315 |
| Other Operating Expenses | 175.99 | 177.02 | 170.28 | 104.53 | 101.52 |
| Operating Expenses | 13,767 | 13,495 | 12,638 | 11,693 | 12,918 |
| Operating Income | -9,684 | -10,666 | -11,792 | -11,497 | -12,861 |
| Interest Expense | -2,144 | -2,092 | -3,037 | -3,925 | -2,656 |
| Interest & Investment Income | 1,532 | 1,635 | 216.6 | 521.6 | 224.84 |
| Currency Exchange Gain (Loss) | 554.02 | 732 | 124.37 | 196.21 | 295.42 |
| Other Non Operating Income (Expenses) | -993.7 | -1,276 | 1,995 | -4,317 | 1,202 |
| EBT Excluding Unusual Items | -10,735 | -11,666 | -12,493 | -19,022 | -13,795 |
| Gain (Loss) on Sale of Investments | -2,918 | -2,896 | -1,412 | 139.47 | 472.78 |
| Gain (Loss) on Sale of Assets | -0 | -0 | -79.33 | -0 | -0 |
| Asset Writedown | -3,475 | -3,486 | -3,164 | - | - |
| Other Unusual Items | -184.27 | 117.02 | 968.31 | 190.52 | - |
| Pretax Income | -17,313 | -17,931 | -16,179 | -18,692 | -13,323 |
| Income Tax Expense | -702.37 | -815.14 | -409.77 | 79.57 | -2,452 |
| Earnings From Continuing Operations | -16,611 | -17,116 | -15,770 | -18,771 | -10,871 |
| Minority Interest in Earnings | -1.39 | -0.89 | - | - | - |
| Net Income | -16,612 | -17,117 | -15,770 | -18,771 | -10,871 |
| Net Income to Common | -16,612 | -17,117 | -15,770 | -18,771 | -10,871 |
| Shares Outstanding (Basic) | 23 | 23 | 18 | 18 | 17 |
| Shares Outstanding (Diluted) | 23 | 23 | 18 | 18 | 17 |
| Shares Change (YoY) | 17.66% | 23.54% | 3.54% | 4.24% | - |
| EPS (Basic) | -727.95 | -757.63 | -862.29 | -1062.74 | -641.54 |
| EPS (Diluted) | -728.32 | -758.00 | -862.29 | -1063.00 | -642.00 |
| Free Cash Flow | -9,692 | -10,536 | -10,092 | -7,024 | -6,449 |
| Free Cash Flow Per Share | -424.73 | -466.34 | -551.82 | -397.69 | -380.57 |
| Gross Margin | 25.99% | 25.93% | 26.57% | 25.66% | 16.47% |
| Operating Margin | -61.63% | -97.75% | -370.30% | -1511.28% | -3697.31% |
| Profit Margin | -105.73% | -156.88% | -495.22% | -2467.37% | -3125.13% |
| Free Cash Flow Margin | -61.69% | -96.56% | -316.91% | -923.33% | -1853.87% |
| EBITDA | -7,357 | -8,577 | -9,880 | -10,184 | -11,747 |
| EBITDA Margin | -46.83% | -78.61% | - | - | - |
| D&A For EBITDA | 2,327 | 2,088 | 1,912 | 1,314 | 1,114 |
| EBIT | -9,684 | -10,666 | -11,792 | -11,497 | -12,861 |
| EBIT Margin | -61.63% | -97.75% | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.